These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 11205196)

  • 1. Serial determinations of aminoterminal propeptide of type III procollagen (PIIINP) and prognosis in ovarian cancer; comparison to CA125.
    Simojoki M; Santala M; Risteli J; Risteli L; Kauppila A
    Anticancer Res; 2000; 20(6C):4655-60. PubMed ID: 11205196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboxyterminal telopeptide of type I collagen (ICTP) in predicting prognosis in epithelial ovarian cancer.
    Simojoki M; Santala M; Risteli J; Kauppila A
    Gynecol Oncol; 2001 Jul; 82(1):110-5. PubMed ID: 11426971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amino-terminal propeptide of type III procollagen: a new prognosis indicator in human ovarian cancer.
    Kauppila A; Puistola U; Risteli J; Risteli L
    Cancer Res; 1989 Apr; 49(7):1885-9. PubMed ID: 2924328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of carboxyterminal telopeptide of type I collagen (ICTP) and CA 125 as predictors of prognosis in ovarian cancer.
    Santala M; Risteli J; Kauppila A
    Anticancer Res; 2004; 24(2C):1057-62. PubMed ID: 15154623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type I and III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer.
    Santala M; Simojoki M; Risteli J; Risteli L; Kauppila A
    Clin Cancer Res; 1999 Dec; 5(12):4091-6. PubMed ID: 10632345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
    Tan XJ; Lang JH; Shen K; Wang L; Wu M; Xu XY
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):9-12. PubMed ID: 18366924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer.
    Høgdall CK; Nørgaard-Pedersen B; Mogensen O
    Anticancer Res; 2002; 22(3):1765-8. PubMed ID: 12168866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis.
    Luo LY; Katsaros D; Scorilas A; Fracchioli S; Bellino R; van Gramberen M; de Bruijn H; Henrik A; Stenman UH; Massobrio M; van der Zee AG; Vergote I; Diamandis EP
    Cancer Res; 2003 Feb; 63(4):807-11. PubMed ID: 12591730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum tetranectin is a significant prognostic marker in ovarian cancer patients.
    Begum FD; Høgdall E; Christensen IJ; Kjaer SK; Blaakaer J; Christensen L; Høgdall C
    Acta Obstet Gynecol Scand; 2010; 89(2):190-8. PubMed ID: 20121334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Kjaerbye-Thygesen A; Gayther S; Jacobs IJ; Høgdall CK
    Gynecol Oncol; 2007 Mar; 104(3):508-15. PubMed ID: 17113137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.
    Nakae M; Iwamoto I; Fujino T; Maehata Y; Togami S; Yoshinaga M; Douchi T
    J Obstet Gynaecol Res; 2006 Jun; 32(3):309-14. PubMed ID: 16764622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of various epithelial tumor markers and a stromal marker in the assessment of cervical carcinoma.
    Tomás C; Risteli J; Risteli L; Vuori J; Kauppila A
    Obstet Gynecol; 1991 Apr; 77(4):566-72. PubMed ID: 2002979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical value of the estimation of growth kinetics of primary ovarian cancer recurrences by CA125 doubling time].
    Riedinger JM; Coudert B; Barillot I; Buffenoir G; Mayer F; Fargeot P; Cuisenier J; Guerrin J
    Bull Cancer; 1997 Sep; 84(9):855-60. PubMed ID: 9435806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary cyclic GMP after treatment of gynecological cancer. A prognostic marker of clinical outcome.
    Orbo A; Hanevik M; Jaeger R; Van Heusden S; Sager G
    Anticancer Res; 2007; 27(4C):2591-6. PubMed ID: 17695420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer.
    Petri AL; Høgdall E; Christensen IJ; Kjaer SK; Blaakaer J; Høgdall CK
    APMIS; 2006 May; 114(5):359-63. PubMed ID: 16725012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma.
    Tate S; Hirai Y; Takeshima N; Hasumi K
    Gynecol Oncol; 2005 Jan; 96(1):143-9. PubMed ID: 15589593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.